Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment

被引：1
|
作者：
Ichaoui, Hamza [1 ,2 ]
Ben Nasr, Sonia [1 ,3 ]
Gargouri, Faten [1 ,4 ]
Zribi, Aref [1 ,3 ]
Hermi, Amine [1 ,2 ]
Fendri, Sana [1 ,3 ]
Balti, Mehdi [1 ,3 ]
Ayari, Jihen [1 ,3 ]
Khiari, Ramzi [1 ,2 ]
Msakni, Issam [1 ,4 ]
Mansouri, Nada [1 ,4 ]
Ghozzi, Samir [1 ,2 ]
Haddaoui, Abderrazek [1 ,3 ]
机构：
[1] Univ Tunis El Manar, Fac Med Tunis, Tunis 1007, Tunisia
[2] Mil Hosp Tunis, Dept Urol, Montfleury 1008, Tunisia
[3] Mil Hosp Tunis, Dept Med Oncol, Montfleury 1008, Tunisia
[4] Mil Hosp Tunis, Dept Pathol, Montfleury 1008, Tunisia
来源：
PAN AFRICAN MEDICAL JOURNAL | 2019年 / 34卷
关键词：
Prostate; squamous cell carcinoma; hormonotherapy; ADENOSQUAMOUS CARCINOMA;
D O I：
10.11604/pamj.2019.34.125.19421
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Squamous cell carcinoma of the prostate is rare and represents 0.5% to 1% of prostatic carcinomas. Transformation of prostatic adenocarcinoma into squamous cell carcinoma after LH-RH agonist intake has been reported in only 8 cases in the literature. To our knowledge, our case is the second pure squamous cell carcinoma observed after hormonotherapy and radiotherapy. We reported a case of a patient with prostatic adenocarcinoma treated by radical prostatectomy followed by radiotherapy. Eleven years later, he had a vesical recurrence of prostatic adenocarcinoma. Our patient had an endoscopic resection followed by injections of Triptorelin. Six months later, he developed a local recurrence of a squamous cell carcinoma.
引用
收藏
页数：7
相关论文
共 50 条
12345